Prudential Financial Inc Revance Therapeutics, Inc. Transaction History

Prudential Financial Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$18.36 - $35.27 $164,560 - $316,125	8,963 New	8,963 $288,000
Q2 2022 Aug 15, 2022	SELL	$11.52 - $20.4 $963,878 - $1.71 Million	-83,670 Reduced 61.63%	52,084 $720,000
Q1 2022 May 13, 2022	BUY	$12.36 - $20.31 $651,050 - $1.07 Million	52,674 Added 63.4%	135,754 $2.65 Million
Q4 2021 Feb 14, 2022	SELL	$12.46 - $27.87 $9,905 - $22,156	-795 Reduced 0.95%	83,080 $1.41 Million
Q3 2021 Nov 15, 2021	BUY	$25.78 - $33.21 $5,413 - $6,974	210 Added 0.25%	83,875 $2.34 Million
Q2 2021 Aug 16, 2021	BUY	$26.8 - $31.84 $7,504 - $8,915	280 Added 0.34%	83,665 $2.48 Million
Q1 2021 May 12, 2021	BUY	$24.03 - $29.97 $601,374 - $750,029	25,026 Added 42.88%	83,385 $2.33 Million
Q4 2020 Feb 16, 2021	SELL	$23.41 - $28.34 $62,176 - $75,271	-2,656 Reduced 4.35%	58,359 $1.65 Million
Q3 2020 Nov 16, 2020	SELL	$23.23 - $34.3 $733,928 - $1.08 Million	-31,594 Reduced 34.12%	61,015 $1.53 Million
Q2 2020 Aug 12, 2020	BUY	$12.6 - $26.55 $492,723 - $1.04 Million	39,105 Added 73.09%	92,609 $2.26 Million
Q1 2020 May 12, 2020	BUY	$12.46 - $27.81 $666,659 - $1.49 Million	53,504 New	53,504 $791,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

Stay updated on Prudential Financial Inc with notifications on news.